CapsoVision to Release Second Quarter 2025 Financial Results on Thursday, August 14, 2025
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
CapsoVision (NASDAQ: CV), a commercial-stage medical technology company specializing in advanced imaging and AI-powered capsule endoscopy solutions, has scheduled its second quarter 2025 financial results release for Thursday, August 14, 2025, after market close.
The company will host a conference call and live webcast at 4:30 PM ET on the same day. Investors can access the call by dialing (800) 715-9871 (domestic) or (646) 307-1963 (international) with conference ID 1668374. A webcast will be available in the investor relations section of CapsoVision's website.
Details
News Market Reaction – CV
The recorded move for CV in the trading session of this news was +1.16%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
- Conference Call Scheduled for Thursday, August 14, 2025 at 4:30 pm ET -
SARATOGA, Calif., July 31, 2025 (GLOBE NEWSWIRE) -- CapsoVision, Inc. (NASDAQ: CV), a commercial-stage medical technology company that develops advanced imaging and artificial intelligence (“AI”) technologies that are deployed in its capsule endoscopy solutions, today announced that the company will release second quarter 2025 financial results on Thursday, August 14, 2025, after the close of market. CapsoVision will host a corresponding conference call and a live webcast at 1:30 pm PT / 4:30 pm ET on the same day to discuss the results and provide a corporate update.
Individuals interested in listening to the conference call may do so by dialing (800) 715-9871 for domestic callers or (646) 307-1963 for international callers and referencing conference ID 1668374, or from the webcast link in the investor relations section of the company's website at www.capsovision.com.
To access the replay, please register via the webcast link on the events page. The webcast will be available in the investor relations section on the company's website for one year following the completion of the call.
About CapsoVision
CapsoVision is a commercial-stage medical technology company focused on developing advanced imaging and AI-enabled solutions to transform the detection and diagnosis of gastrointestinal diseases. Its flagship product, CapsoCam Plus®, is a wire-free, panoramic capsule endoscope that enables high-resolution visualization of the small bowel and supports cloud-based or direct capsule video retrieval. The Company’s next pipeline product, CapsoCam Colon, is designed to enable non-invasive colon imaging and polyp detection. With a proprietary platform targeted to expand across multiple GI indications, including esophageal and pancreatic disorders, CapsoVision is advancing a new era in capsule-based diagnostics. For more information on CapsoVision, please visit www.capsovision.com.
Investor Relations Contact
Leigh Salvo
New Street Investor Relations
Investors@CapsoVision.com
Kevin Lundquist
Chief Financial Officer, CapsoVision, Inc.
kml@capsovision.com
Media Contact
Leslie Strickler and Paul Spicer
Être Communications
leslies@etrecommunications.com | (804) 240-0807
pauls@etrecommunications.com | (804) 503-9231
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.